Mark Wunderlich

Publication Activity (10 Years)

Years Active: 2018-2023
Publications (10 Years): 13

Top Topics

Allogeneic Hematopoietic Stem Cell Transplantation

Induced Apoptosis

Immune Response

Endoplasmic Reticulum Stress

Top Venues

Cancer discovery

Science translational medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Sarai T Dean, Chiharu Ishikawa, Xiaoqin Zhu, Sean Walulik, Timothy Nixon, Jessica K Jordan, Samantha Henderson, Michael Wyder, Nathan Salomonis, Mark Wunderlich, Kenneth D Greis, Daniel T Starczynowski, Andrew G Volk
Repression of TRIM13 by chromatin assembly factor CHAF1B is critical for AML development. Blood advances (2023)
Sarai T Dean, Chiharu Ishikawa, Xiaoqin Zhu, Sean Walulik, Timothy Nixon, Jessica K Jordan, Samantha Henderson, Michael Wyder, Nathan Salomonis, Mark Wunderlich, Kenneth D Greis, Daniel T Starczynowski, Andrew G Volk
Repression of TRIM13 by chromatin assembly factor CHAF1B is critical for AML development. Blood advances (2023)
Joshua Ruina Bennett, Chiharu Ishikawa, Puneet Agarwal, Jennifer Yeung, Avery M Sampson, Emma Uible, Eric J Vick, Lyndsey C Bolanos, Kathleen M Hueneman, Mark Wunderlich, Amal Kolt, Kwangmin Choi, Andrew G Volk, Kenneth D Greis, Jan S Rosenbaum, Scott Hoyt, Craig J Thomas, Daniel T Starczynowski
Paralog-specific signaling by IRAK1/4 maintains MyD88-independent functions in MDS/AML. Blood (2023)
Joshua Ruina Bennett, Chiharu Ishikawa, Puneet Agarwal, Jennifer Yeung, Avery M Sampson, Emma Uible, Eric J Vick, Lyndsey C Bolanos, Kathleen M Hueneman, Mark Wunderlich, Amal Kolt, Kwangmin Choi, Andrew G Volk, Kenneth D Greis, Jan S Rosenbaum, Scott Hoyt, Craig J Thomas, Daniel T Starczynowski
Paralog-specific signaling by IRAK1/4 maintains MyD88-independent functions in MDS/AML. Blood (2023)
Jana M Ellegast, Gabriela Alexe, Amanda Hamze, Shan Lin, Hannah J Uckelmann, Philipp J Rauch, Maxim Pimkin, Linda S Ross, Neekesh V Dharia, Amanda L Robichaud, Amy Saur Conway, Delan Khalid, Jennifer A Perry, Mark Wunderlich, Lina Benajiba, Yana Pikman, Behnam Nabet, Nathanael S Gray, Stuart H Orkin, Kimberly Stegmaier
Unleashing Cell-Intrinsic Inflammation as a Strategy to Kill AML Blasts. Cancer discovery 12 (7) (2022)
Laura Barreyro, Avery M Sampson, Chiharu Ishikawa, Kathleen M Hueneman, Kwangmin Choi, Mario A Pujato, Somchai Chutipongtanate, Michael Wyder, Wendy D Haffey, Eric O'Brien, Mark Wunderlich, Vighnesh Ramesh, Ellen K Gagliani, Cem Meydan, Yaseswini Neelamraju, Lyndsey C Bolanos, Susanne Christie, Molly A Smith, Madeline Niederkorn, Tomoya Muto, Santosh Kesari, Francine E Garrett-Bakelman, Boris Bartholdy, Britta Will, Matthew T Weirauch, James C Mulloy, Zartash Gul, Stephen Medlin, Rhett A Kovall, Ari M Melnick, John P Perentesis, Kenneth D Greis, Elmar Nurmemmedov, William L Seibel, Daniel T Starczynowski
Blocking UBE2N abrogates oncogenic immune signaling in acute myeloid leukemia. Science translational medicine 14 (635) (2022)
Mohammad Azhar, Zachary Kincaid, Meenu Kesarwani, Jacob Menke, Joshua Sweiterman, Sekhu Ansari, Angela Reaves, Arhama Ahmed, Rammsha Shahzad, Areeba Khan, Nuha Syed, Noor Amir, Mark Wunderlich, Tahir Latif, William L Seibel, Mohammad Azam
Rational polypharmacological targeting of FLT3, JAK2, ABL, and ERK1 suppresses the adaptive resistance to FLT3 inhibitors in AML. Blood advances (2022)
Yuting Tang, Qian Xu, Liang Hu, Xiaomei Yan, Xiaomin Feng, Asumi Yokota, Weinan Wang, Di Zhan, Durga Krishnamurthy, David E Ochayon, Lijun Wen, Li Huo, Huimin Zeng, Yingwan Luo, L Frank Huang, Mark Wunderlich, Jiwang Zhang, Eric Vivier, Jian-Feng Zhou, Stephen N Waggoner, Gang Huang
Tumor Microenvironment-Derived R-spondins Enhance Anti-Tumor Immunity to Suppress Tumor Growth and Sensitize for Immune Checkpoint Blockade Therapy. Cancer discovery (2021)
Mohammad Azhar, Zachary Kincaid, Meenu Kesarwani, Arhama Ahmed, Mark Wunderlich, Tahir Latif, Daniel Starczynowski, Mohammad Azam
Momelotinib is a highly potent inhibitor of FLT3-mutant AML. Blood advances (2021)
Shan Lin, Clement Larrue, Nastassja K Scheidegger, Bo Kyung Alex Seong, Neekesh V Dharia, Miljan Kuljanin, Caroline S Wechsler, Guillaume Kugener, Amanda L Robichaud, Amy Saur Conway, Thelma Mashaka, Sarah Mouche, Biniam Adane, Jeremy Adam Ryan, Joseph D Mancias, Scott T Younger, Frederica Piccioni, Lynn H Lee, Mark Wunderlich, Anthony G Letai, Jerome Tamburini, Kimberly Stegmaier
An in vivo CRISPR screening platform for prioritizing therapeutic targets in AML. Cancer discovery (2021)
Katelyn Melgar, Morgan M Walker, LaQuita M Jones, Lyndsey C Bolanos, Kathleen M Hueneman, Mark Wunderlich, Jian-Kang Jiang, Kelli M Wilson, Xiaohu Zhang, Patrick Sutter, Amy Wang, Xin Xu, Kwangmin Choi, Gregory J Tawa, Donald Lorimer, Jan Abendroth, Eric O'Brien, Scott B Hoyt, Ellin Berman, Christopher A Famulare, James C Mulloy, Ross L Levine, John P Perentesis, Craig J Thomas, Daniel T Starczynowski
Overcoming adaptive therapy resistance in AML by targeting immune response pathways. Science translational medicine 11 (508) (2020)
Mark Wunderlich, Nicole Manning, Christina Sexton, Anthony Sabulski, Luke Byerly, Eric O'Brien, John P Perentesis, Benjamin Mizukawa, James C Mulloy
Improved chemotherapy modeling with RAG-based immune deficient mice. PloS one 14 (11) (2019)
Mark Wunderlich, Fu-Sheng Chou, Christina Sexton, Pietro Presicce, Claire A Chougnet, Julio Aliberti, James C Mulloy
Improved multilineage human hematopoietic reconstitution and function in NSGS mice. PloS one 13 (12) (2018)